Bolt Biotherapeutics (NASDAQ:BOLT – Get Free Report) and CAMP4 Therapeutics (NASDAQ:CAMP – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.
Profitability
This table compares Bolt Biotherapeutics and CAMP4 Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Bolt Biotherapeutics | -611.47% | -154.11% | -57.59% |
| CAMP4 Therapeutics | -2,276.33% | -182.39% | -74.87% |
Insider & Institutional Ownership
86.7% of Bolt Biotherapeutics shares are held by institutional investors. 9.4% of Bolt Biotherapeutics shares are held by insiders. Comparatively, 21.7% of CAMP4 Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Risk and Volatility
Bolt Biotherapeutics has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500. Comparatively, CAMP4 Therapeutics has a beta of 0.28, meaning that its share price is 72% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings and target prices for Bolt Biotherapeutics and CAMP4 Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bolt Biotherapeutics | 1 | 0 | 2 | 0 | 2.33 |
| CAMP4 Therapeutics | 1 | 1 | 8 | 1 | 2.82 |
Bolt Biotherapeutics currently has a consensus price target of $14.50, indicating a potential upside of 195.32%. CAMP4 Therapeutics has a consensus price target of $10.44, indicating a potential upside of 175.58%. Given Bolt Biotherapeutics’ higher probable upside, analysts plainly believe Bolt Biotherapeutics is more favorable than CAMP4 Therapeutics.
Earnings & Valuation
This table compares Bolt Biotherapeutics and CAMP4 Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bolt Biotherapeutics | $7.70 million | 1.66 | -$33.38 million | ($14.97) | -0.33 |
| CAMP4 Therapeutics | $5.32 million | 44.71 | -$80.40 million | ($2.14) | -1.77 |
Bolt Biotherapeutics has higher revenue and earnings than CAMP4 Therapeutics. CAMP4 Therapeutics is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Bolt Biotherapeutics beats CAMP4 Therapeutics on 9 of the 15 factors compared between the two stocks.
About Bolt Biotherapeutics
Bolt Biotherapeutics is a clinical-stage biotechnology company based in Redwood City, California. It develops immunotherapies designed to direct the body’s immune system against cancer. The company’s Boltbody platform is designed to pair tumor-targeting antibodies with immune-stimulating components. Its pipeline has included BDC-3042, an investigational antibody intended to activate macrophages, immune cells that can help recognize and attack tumors. Bolt has also developed BDC-1001, an investigational HER2-targeting immune-stimulating antibody conjugate.
About CAMP4 Therapeutics
CAMP4 Therapeutics is a clinical-stage biotechnology company developing RNA-based medicines for genetic diseases in which the body produces too little of an essential protein. The company’s research focuses on increasing the expression of selected genes to address these protein deficiencies. Its Regulatory Action on RNA (RAP) platform is designed to identify regulatory RNAs that influence gene expression. CAMP4 uses antisense oligonucleotides to target these RNAs, with the goal of adjusting the activity of disease-related genes.
Receive News & Ratings for Bolt Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bolt Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
